We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

FUJIREBIO

Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App




Fujirebio and Sysmex Collaborate for Development and Advancement of Immunoassay

By LabMedica International staff writers
Posted on 18 Dec 2023
Print article
Image: Fujirebio and Sysmex have signed an agreement for the supply of reagent raw materials in the field of immunoassay (Photo courtesy of 123RF)
Image: Fujirebio and Sysmex have signed an agreement for the supply of reagent raw materials in the field of immunoassay (Photo courtesy of 123RF)

Fujirebio Holdings (Tokyo, Japan) and Sysmex Corporation (Kobe, Japan) have signed an agreement for the mutual supply of reagent raw materials owned by both companies. The agreement is based on a basic agreement on business collaboration in the field of immunoassay signed by the two companies in October 2023.

In October 2023, Fujirebio and Sysmex entered into a basic agreement on business collaboration in the field of immunoassay, intending to promote cooperation to accelerate their global expansion, and to contribute to the development and advancement of immunoassay. To promote specific initiatives, the two companies signed a Contract Development and Manufacturing Organization (CDMO) agreement in November 2023 related to dedicated reagents for the HISCL-Series automated immunoassay system, involving the development of reagents for cerebral-spinal fluid-based and blood-based testing in the field of neurodegenerative diseases, including Alzheimer’s disease.

As per the terms of the agreement, Fujirebio and Sysmex will mutually supply a wide range of reagent materials owned by each company, primarily antigens and antibodies, which are the key raw materials of immunoassay reagents. This will allow the CDMO to speed up reagent development, lower costs, and maximize the value of raw material assets while building a stable supply system to meet the global demand growth in the future and prepare for raw material procurement risk in case of an emergency. By strengthening cooperation in the area of reagent materials, Fujirebio and Sysmex will promote the mutual utilization of their high-quality reagent materials. Additionally, they will continue to work together in the future to develop new parameters and technologies.

Related Links:
Fujirebio Holdings
Sysmex Corporation

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.